Respiratory syncytial virus pseudovirus and preparation method thereof
By introducing respiratory syncytial virus with specific amino acid mutations to integrate pre-fusion F proteins, modifying its conformation to improve infection intensity, and preparing pseudoviruses through plasmid recombination and virus packaging technology, the inadequate infection and safety of F proteins in the prior art is solved. , achieving efficient expression and improvement of infection, providing new possibilities for vaccines and drugs.
Patent Information
- Application Number
- CN202311839808.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-12-28
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2043-12-28
AI Technical Summary
The existing F protein before fusion of respiratory syncytial virus is insufficient in terms of infection, and the use of wild-type viruses has safety problems and high laboratory environment requirements, making it difficult to achieve efficient expression and improve infection.
By introducing amino acid mutations N67I, N116Q, S215P, D486N, the conformation of the F protein before fusion of respiratory syncytial virus is modified to stabilize the conformation before fusion, thereby increasing the infection of F protein and preparing through plasmid recombination and virus packaging technology A highly efficient expression of respiratory syncytial virus pseudovirus.
The efficient expression and infection intensity of F protein before the fusion of respiratory syncytial virus is achieved, providing a safe and efficient experimental tool and potential vaccine or drug preparation methods.
Smart Images

Figure CN117886950B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of biotechnology, and in particular to a respiratory syncytial virus pseudovirus and a preparation method thereof. Background Art
[0002] Respiratory Syncytial Virus (RSV) is a non-segmented single-stranded negative-sense RNA virus belonging to the family Paramyxoviridae, the subfamily Pneumovirinae, and the genus Pneumovirus. The outer layer of the virus particle is a lipid capsule, and the inner layer is a viral nucleocapsid. The virus particle consists of an envelope, a nucleocapsid, and a core. The envelope of the respiratory syncytial virus is inlaid with three key proteins, namely SH protein, F protein, and G protein. Among them, the F protein has two forms: pre-fusion and post-fusion. The nucleocapsid is composed of capsomeres, and the viral core is a complex composed of viral genomic RNA and non-structural proteins such as N, P, and L.
[0003] RSV is an important pathogen of acute respiratory tract infection in infants, immunocompromised people and the elderly. It is prone to repeated infection, rapid transmission and rapid disease progression. In the early stage of infection, the virus mainly replicates in the upper respiratory tract, causing nasal congestion, which may be accompanied by clinical symptoms such as fever, fatigue and headache. A small number of patients will develop lower respiratory tract infection, causing capillaritis and pneumonia, manifested by symptoms such as headache, fatigue and fever. Severe patients are prone to serious complications, including respiratory insufficiency, gastrointestinal insufficiency, apnea and viral myocarditis and other related symptoms.
[0004] The F protein is a type I transmembrane glycoprotein that contains a signal peptide, a signal peptide cleavage site, an F2 region, a polypeptide cleavage region, and an F1 region. The F protein trimer contains two conformations: pre-fusion F protein (Pre-F) and post-fusion F protein (Post-F). Pre-F is a metastable structure. When the virus fuses with the cell, Pre-F transforms into a stable Post-F. The pre-fusion conformation of the F protein has a stronger infection power, while the post-fusion conformation of the F protein is more stable but less infectious. Previous studies mainly used antibody neutralization experiments with wild-type respiratory syncytial virus and used it to infect hosts to study the infection mechanism. However, the use of wild-type respiratory syncytial virus itself has safety issues and requires a high laboratory environment.
[0005] Chinese patent CN116284266A discloses a mutant respiratory syncytial virus prefusion F protein and its application. The mutant respiratory syncytial virus prefusion F protein has the following mutations compared to the wild-type respiratory syncytial virus prefusion F protein: (a) at least one amino acid residue in the F1 subunit and / or F2 subunit is replaced by cysteine, (b) the amino acid residues 104-144 of the wild-type respiratory syncytial virus prefusion F protein are partially or completely replaced by a connecting peptide, and the amino acid residue length of the connecting peptide is at least two. The mutant respiratory syncytial virus prefusion F protein of the invention has higher neutralizing antibody binding activity and thermal stability than similar products. However, its infection strength has not been significantly improved.
[0006] Therefore, how to modify the F protein to achieve its efficient expression and improve the infection strength is an urgent problem to be solved in this field. Summary of the invention
[0007] The purpose of the present invention is to provide a respiratory syncytial virus pre-fusion F protein, transform the conformation of the respiratory syncytial virus pre-fusion F protein to stabilize it in the pre-fusion conformation, thereby increasing the infection strength of the F protein.
[0008] To achieve the above-mentioned object of the invention, the technical solution of the present invention is as follows:
[0009] On the one hand, the present invention provides a respiratory syncytial virus prefusion F protein, which contains at least two of the following mutations compared with the amino acid sequence such as SEQ ID NO: 6: N67I, N116Q, S215P, D486N.
[0010] Preferably, the amino acid sequence of the respiratory syncytial virus pre-fusion F protein is as shown in SEQ ID NO:1.
[0011] In yet another aspect, the present invention provides a nucleic acid molecule encoding the above-mentioned respiratory syncytial virus pre-fusion F protein.
[0012] Specifically, the nucleic acid molecule comprises one or more codon-optimized nucleic acid molecules.
[0013] In yet another aspect, the present invention provides a vector comprising the above-mentioned nucleic acid molecule.
[0014] Preferably, the vector includes but is not limited to plasmid and virus.
[0015] Furthermore, the vector is a viral vector.
[0016] Furthermore, the viral vector is an influenza virus vector, a retrovirus vector or an adenovirus vector.
[0017] Preferably, the present invention provides a host cell, wherein the host cell comprises the above-mentioned respiratory syncytial virus pre-fusion F protein or the above-mentioned nucleic acid molecule or the above-mentioned vector.
[0018] Preferably, the host cell is selected from prokaryotic cells or eukaryotic cells.
[0019] Furthermore, the prokaryotic cells are selected from Escherichia coli cells.
[0020] Furthermore, the eukaryotic cells include mammalian cells.
[0021] Furthermore, the mammalian cells include mouse cells and human cells.
[0022] Specifically, the mammalian cells are human cells, and the human cells include hematopoietic cells, epithelial cells, liver cells, and neural cells.
[0023] In another aspect, the present invention provides a respiratory syncytial virus pseudovirus, comprising the above-mentioned respiratory syncytial virus pre-fusion F protein.
[0024] In another aspect, the present invention provides a method for preparing a respiratory syncytial virus pseudovirus, comprising the following steps:
[0025] (1) Plasmid pcDNA3.1+ was used as a vector, and restriction enzymes BamHI and EcoRI were used to obtain a linearized vector. The linearized pcDNA3.1+ vector was connected with SEQ ID NO.1, SEQ ID NO:2, and SEQ ID NO:3 by homologous recombination to obtain pcDNA3.1-pre F plasmid, pcDNA3.1-G plasmid, and pcDNA3.1-ZsGreen-IRES-Luc2 plasmid, respectively;
[0026] (2) Pseudovirus packaging was performed in 293T cells, and pcDNA3.1-pre F plasmid, pcDNA3.1-G plasmid, pcDNA3.1-ZsGreen-IRES-Luc2 plasmid and psPAX2 plasmid were added and mixed, and then 1xPEI was added and mixed to obtain a transfection mixture;
[0027] (3) adding the transfection mixture to the culture dish for transfection;
[0028] (4) Centrifugation, collecting the supernatant of the cell culture medium, adding virus protection solution for resuspending, and then adding universal nuclease to obtain respiratory syncytial virus pseudovirus.
[0029] Preferably, cell transfection can be performed in step (2) only when the 293T cell density is about 90%, there is no mycoplasma and the cells are in good condition.
[0030] Preferably, before transfection in step (2), the DMEM medium containing 2% FBS serum is replaced in each dish.
[0031] Preferably, the amount of plasmid added in step (2) is 2.5ug of psPAX2 plasmid, 4.5ug of pcDNA3.1-ZsGreen-IRES-Luc2 plasmid, 2ug of pcDNA3.1-pre F plasmid, and 2ug of pcDNA3.1-G plasmid.
[0032] Preferably, the transfection time in step (3) is 6-8 hours.
[0033] Preferably, the centrifugal speed in step (4) is 50000 x g and the centrifugal time is 2 h.
[0034] In another aspect, the present invention provides the use of the above-mentioned respiratory syncytial virus pre-fusion F protein or the above-mentioned nucleic acid molecule or the above-mentioned vector or the above-mentioned host cell or the above-mentioned respiratory syncytial virus pseudovirus or the respiratory syncytial virus pseudovirus prepared by the above-mentioned preparation method in the preparation of a drug for treating, preventing or assisting in the treatment of respiratory syncytial virus infection.
[0035] In another aspect, the present invention provides the use of the above-mentioned respiratory syncytial virus pre-fusion F protein or the above-mentioned nucleic acid molecule or the above-mentioned vector or the above-mentioned host cell or the above-mentioned respiratory syncytial virus pseudovirus or the respiratory syncytial virus pseudovirus prepared by the above-mentioned preparation method in the preparation of a vaccine for preventing respiratory syncytial virus infection.
[0036] In another aspect, the present invention provides a pharmaceutical composition comprising the above-mentioned respiratory syncytial virus pre-fusion F protein or the above-mentioned nucleic acid molecule or the above-mentioned vector or the above-mentioned host cell or the above-mentioned respiratory syncytial virus pseudovirus or the respiratory syncytial virus pseudovirus prepared by the above-mentioned preparation method.
[0037] Preferably, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
[0038] Furthermore, the pharmaceutically acceptable carrier includes, but is not limited to, excipients, buffers, emulsifiers, stabilizers, diluents, binders, and preservatives.
[0039] Specifically, the excipient is selected from at least one of microcrystalline cellulose, lactose, pregelatinized starch, cyclodextrin, carboxymethyl cellulose and mannitol.
[0040] Specifically, the buffer is selected from at least one of sodium dihydrogen phosphate, sodium bicarbonate, ammonium bicarbonate, sodium acetate, citrate, histidine, and succinate.
[0041] Specifically, the emulsifier is selected from at least one of magnesium stearate, zinc stearate, calcium stearate, glyceryl stearate, sorbitan isostearate, sorbitan oleate, glyceryl oleate, and polyglyceryl-3 polyricinoleate.
[0042] Specifically, the stabilizer is selected from at least one of acacia gum, agar, alginic acid, cellulose ether, and carboxymethyl chitosan.
[0043] Specifically, the diluent is selected from at least one of erythritol, mannitol, sorbitol, xylitol, lactose, sucrose, corn starch, potato starch, calcium phosphate, calcium citrate, and crystalline cellulose.
[0044] Specifically, the binder is selected from at least one of ethanol, starch slurry, syrup, hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, sodium alginate, and polyvinyl pyrrolidone.
[0045] Specifically, the preservative is selected from at least one of methylparaben, propylparaben, methylparaben, ethylparaben, propylparaben, chlorobutanol, thimerosal, mercuric cyanide, phenoxyethanol, chlorhexidine, benzoic acid, sodium benzoate, chlorocresol, benzalkonium bromide, benzalkonium chloride, and ethylparaben.
[0046] Preferably, the dosage form of the drug is selected from any one of injection, tablet, capsule, oral liquid dosage form, granule, ointment, suspension, powder, emulsion, solution, pill, suppository, and aerosol.
[0047] In yet another aspect, the present invention provides a vaccine comprising the above-mentioned respiratory syncytial virus pre-fusion F protein or the above-mentioned nucleic acid molecule or the above-mentioned vector or the above-mentioned host cell or the above-mentioned respiratory syncytial virus pseudovirus or the respiratory syncytial virus pseudovirus prepared by the above-mentioned preparation method.
[0048] Preferably, the vaccine may further comprise an adjuvant.
[0049] The beneficial effects of the present invention are:
[0050] The present invention provides a respiratory syncytial virus pre-fusion F protein, which is based on the wild-type respiratory syncytial virus pre-fusion F protein and introduces four mutant pseudoviruses, namely, N67I, N116Q, S215P and D486N. The conformation of the modified respiratory syncytial virus pre-fusion F protein is stabilized in the pre-fusion conformation, thereby increasing the infection strength of the F protein and achieving its efficient expression. BRIEF DESCRIPTION OF THE DRAWINGS
[0051] Figure 1 This is a schematic diagram of the respiratory syncytial virus pseudovirus packaging, transfection and detection process.
[0052] Figure 2 This is the map of pcDNA3.1-pre F plasmid.
[0053] Figure 3 This is the pcDNA3.1-G plasmid map.
[0054] Figure 4 This is the plasmid map of pcDNA3.1-ZsGreen-IRES-Luc2.
[0055] Figure 5 This is an agarose gel image of respiratory syncytial virus pseudovirus.
[0056] Figure 6 This is a graph of the copy number of respiratory syncytial virus pseudovirus detected by qPCR.
[0057] Figure 7 Fluorescence images of A549 and Hep-2 cell lines infected with respiratory syncytial virus pseudovirus.
[0058] Figure 8 This is a gel imaging image of respiratory syncytial virus pseudovirus protein.
[0059] Fig. 9 Bar graph for RSV pseudovirus dual-luciferase assay data analysis. DETAILED DESCRIPTION
[0060] In order to make the technical means, creative features, purpose and efficacy of the present invention easy to understand, the present invention is further explained in conjunction with specific embodiments below, but the following embodiments are only preferred embodiments of the present invention, not all. Based on the embodiments in the implementation mode, other embodiments obtained by those skilled in the art without creative work all belong to the protection scope of the present invention. In the following embodiments, unless otherwise specified, the operating methods used are conventional operating methods, the equipment used are conventional equipment, and the equipment materials used in each embodiment are the same.
[0061] In the present invention specification Figure 1 This is a schematic diagram of the respiratory syncytial virus pseudovirus packaging, transfection and detection process.
[0062] Example 1 Construction of Respiratory Syncytial Virus Pseudovirus-related Plasmids
[0063] (1) The whole genome synthesis method obtained the following sequence, as shown in Table 1.
[0064] Table 1.
[0065]
[0066] (2) Plasmid pcDNA3.1+ was used as a vector, and the linearized vector was obtained by restriction endonuclease BamHI and EcoRI. The linearized pcDNA3.1+ vector was connected with the synthesized SEQ ID NO.1 by homologous recombination to obtain pcDNA3.1-preF plasmid. The map is shown in FIG. Figure 2 shown.
[0067] (3) Plasmid pcDNA3.1+ was used as a vector, and the linearized vector was obtained by restriction endonuclease BamHI and EcoRI. The linearized pcDNA3.1+ vector was connected with the synthesized SEQ ID NO.2 by homologous recombination to obtain pcDNA3.1-G plasmid. The map is shown in Figure 3 shown.
[0068] (4) Plasmid pcDNA3.1+ was used as a vector, and restriction endonucleases BamHI and EcoRI were used to obtain a linearized vector. The linearized pcDNA3.1+ vector was ligated with the synthesized SEQ ID NO.3 by homologous recombination to obtain a pcDNA3.1-ZsGreen-IRES-Luc2 plasmid. The map is shown in FIG. Figure 4 shown.
[0069] Take 1ug of the constructed plasmid and run 1% agarose gel electrophoresis at 120V for 30min. The plasmid with the correct electrophoresis band was sent for first-generation genome sequencing. The sequencing was completed by Tianlin Company. The results of agarose gel electrophoresis are shown in Figure 5 .
[0070] Example 2 Respiratory syncytial virus pseudovirus packaging experiment
[0071] (1) Observe the status of 293T cells under a microscope before transfection. Cell transfection can be performed if the density is around 90%, there is no mycoplasma, and the growth status is good;
[0072] (2) Before transfection, replace the medium of each 10 cm dish with 10 mL of DMEM medium containing 2% FBS serum to reduce the effect of serum on plasmid transfection;
[0073] (3) Experimental groups and plasmid dosages are as follows (the psPAX2 plasmid in the table below was purchased from Addgene, catalog number 12260):
[0074] Table 2.
[0075]
[0076]
[0077] (4) Add the required amount of plasmid and 1xPEI in the above table into the corresponding 1.5mL EP tube containing 1mL 1xPBS / dish, add the plasmid first and mix well, then add 1xPEI (purchased from HARVEYBIO, catalog number 49553-93-7) and mix well, let stand for 15 minutes to obtain the transfection mixture;
[0078] (5) The transfection mixture was added dropwise to a 10 cm dish and the medium was replaced with 10 mL of DMEM medium containing 2% FBS serum 8 h after transfection;
[0079] (6) 48 hours after transfection, the cell culture supernatant was collected and centrifuged at 50,000×g for 2 hours. The cells were resuspended in 100 ul 1xPBS (purchased from Gibco, catalog number 70011044). At the same time, 25 ul universal nuclease (purchased from Zrbiorise, catalog number ZRXX12688) was added to each 10 cm dish and treated at 37°C for 1 hour to eliminate free DNA and RNA. The purified respiratory syncytial virus pseudoviruses were then filtered and purified and named Pre-F+G virus, Pre-F virus, and G virus, respectively.
[0080] Example 3 Detection of respiratory syncytial virus load
[0081] (1) Viral nucleic acid extraction kit (purchased from Beaverbio, Cat. NO. 70406) was used to extract RNA carried by respiratory syncytial virus pseudoviruses RSV pre F&G, RSV pre F, and RSV G, respectively. The RNA carried by the three viruses was the same (including the mRNA of ZsGreen and dual Luciferase). The specific extraction method was carried out according to the instructions.
[0082] (2) RNA was subjected to qPCR using a one-step RT-qPCR kit (purchased from Novartis, HiScript II One Step qRT-PCR SYBR Green Kit, catalog number: Q221-01), which can simultaneously perform RNA reverse transcription and qPCR.
[0083] (3) The qPCR primer sequences for detecting dual Luciferase mRNA are as follows:
[0084] Table 3.
[0085] Sequence number synthetic sequence SEQ ID NO:4 Forward Primer:CGCACATATCGAGGTGGACA SEQ ID NO:5 Reverse Primer:GCAAGCTATTCTCGCTGCAC
[0086] (4) The 20ul reaction system of RT-qPCR is as follows:
[0087] Table 4 Reaction system
[0088]
[0089] Prepare and mix the reaction system on ice according to the above table.
[0090] (5) The RT-qPCR reaction procedure is as follows:
[0091] Table 5 Reaction procedure
[0092]
[0093] Set up the qPCR reaction program according to the above table, perform the qPCR reaction, and export the data for analysis. Figure 6 The results show that the copy number of Pre-F virus is higher than that of Pre-F+G virus and G virus.
[0094] Example 4 Detection of the infection intensity of respiratory syncytial virus pseudovirus
[0095] (1) A549 and Hep-2 cell lines were cultured using DMEM medium containing 10% serum. After the cells were revived for more than three generations, the cell growth status was observed. When the cells grew to a density of 80%-90% and the cells were in good condition, they were plated in six-well plates, with a total of 6 wells and a plating density of 30%-40%.
[0096] (2) On the second day, 20 μl of RSV pseudovirus and 1× infection aid reagent (purchased from Biosharp, catalog number BL628A) were mixed and added to a six-well plate. The six-well plate was shaken by the cross-shaking method and then placed in a 37° C. cell culture incubator containing 5% CO 2 for culture.
[0097] (3) After about 12 hours of infection, the medium was replaced with 2 mL of DMEM containing 10% serum for culture. After 72 hours of infection, a fluorescence microscope was used to take a picture. The fluorescence image of the RSV pseudovirus is shown in the figure below. Figure 7 As shown in the results, it can be seen that the fluorescence intensity of Pre-F+G virus is higher than that of Pre-F virus and G virus.
[0098] Example 5 Identification of respiratory syncytial virus pseudovirus protein (WB)
[0099] (1) 60 μl of the virus solution in Example 2 was added with 20 μl of 4x SDS loading buffer (purchased from Takara, catalog number 9173), mixed and boiled at 100°C for 10 min for denaturation treatment. After denaturation, the mixture was centrifuged at 12,000 rpm for 2 min to remove impurities.
[0100] (2) Load 20 μl of sample for polyacrylamide gel electrophoresis at 120 V for 1 h 10 min;
[0101] (3) After electrophoresis, transfer to a PVDF membrane is performed. The transfer condition is 100 mA for 1 h 30 min or until there is no obvious protein marker residue on the gel.
[0102] (4) The PVDF membrane after transfer was blocked with 5% skimmed milk powder and incubated on a 40 rpm rocker for 1 h;
[0103] (5) The incubated PVDF was washed with 1xPBST (purchased from Solarbio, catalog number P1031) and then incubated with the corresponding F protein (purchased from abcam, catalog number ab9110) and G protein antibodies (purchased from abcam, catalog number ab94966) at 4°C overnight. The dilution ratio of F protein to G protein was 1:1000.
[0104] (6) The PVDF membrane after primary antibody incubation was washed with 1xPBST three times, each time on a horizontal shaker at 80 rpm for 5 min;
[0105] (7) After cleaning, the PVDF membrane was incubated with the corresponding secondary antibody and placed on a 40 rpm horizontal shaker for 1 h. The dilution ratio of the secondary antibody was 1:10000.
[0106] (8) The PVDF membrane after secondary antibody incubation was washed with 1xPBST three times, each time on a horizontal shaker at 80 rpm for 5 min;
[0107] (9) After washing, the PVDF membrane is evenly dripped with luminescent liquid and placed in a protein gel imaging instrument to take luminescent pictures. The specific protein gel imaging picture is as follows: Figure 8 As shown, the data show that the band positions of F protein and G protein are consistent with the actual ones, proving that F protein and G protein are successfully expressed. The Control is the 1x virus protection solution used to resuspend the purified virus.
[0108] Example 6 Expression of respiratory syncytial virus pseudovirus
[0109] (1) A549 and Hep-2 cell lines were cultured in DMEM medium containing 10% serum. After the cells were revived for more than three generations, the cell growth status was observed. When the cells grew to a density of 80%-90% and the cells were in good condition, they were plated in 96-well plates. Each virus was plated in 3 replicates for a total of 9 wells, with a plating density of 30%-40%.
[0110] (2) On the next day, 10 ul of RSV pseudovirus and 1x infection-aiding reagent were mixed and added to a 96-well plate. The plate was shaken and placed in a 37°C cell culture incubator containing 5% CO2 for culture.
[0111] (3) 72 hours after infection, cells were washed with 1xPBS (purchased from Gibco, catalog number 10-010-023), and after trypsin digestion, cells were collected and centrifuged at 1000 rpm for 5 min. After centrifugation, the supernatant was discarded, and each cell pellet was lysed with 50 ul of lysis buffer in a dual luciferase assay kit (purchased from Promega, catalog number E1910) and transferred to an ELISA plate. The plate was placed in an ELISA reader and the program was set for detection. A bar graph was drawn based on the detection data for analysis. The bar graph is shown in Figure 2. Fig. 9 As shown, the data show that the virus has a higher fluorescence intensity than the control, where the control is the untreated wild-type cell A549 WT / Hep-2 WT.
[0112] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. A respiratory syncytial virus pseudovirus, It is characterized in that The pseudovirus includes the respiratory syncytial virus pre-fusion F protein and G protein; compared with the amino acid sequence encoded by SEQ ID NO:6, the pre-fusion F protein has four mutations: N67I, N116Q, S215P, and D486N; the G protein encoding sequence is shown in SEQ ID NO:2; The preparation method of the respiratory syncytial virus pseudovirus comprises the following steps: (1) Plasmid pcDNA3.1+ was used as a vector, and restriction endonucleases BamHI and EcoRI were used to obtain a linearized vector. The linearized pcDNA3.1+ vector was connected with SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3 by homologous recombination to obtain pcDNA3.1-pre F plasmid, pcDNA3.1-G plasmid, and pcDNA3.1-ZsGreen-IRES-Luc2 plasmid, respectively; (2) Pseudovirus packaging was performed in 293T cells, and pcDNA3.1-pre F plasmid, pcDNA3.1-G plasmid, pcDNA3.1-ZsGreen-IRES-Luc2 plasmid and psPAX2 plasmid were added and mixed, and then 1xPEI was added and mixed to obtain a transfection mixture; (3) adding the transfection mixture to the culture dish for transfection; (4) Centrifugation, collecting the supernatant of the cell culture medium, adding virus protection solution for resuspending, and then adding universal nuclease to obtain respiratory syncytial virus pseudovirus.
2. The respiratory syncytial virus pseudovirus according to claim 1, It is characterized in that The respiratory syncytial virus pre-fusion F protein coding sequence is shown in SEQ ID NO:
1.
3. Use of the respiratory syncytial virus pseudovirus according to any one of claims 1 to 2 in the preparation of a vaccine for preventing respiratory syncytial virus infection.
4. A pharmaceutical composition, It is characterized in that The pharmaceutical composition comprises the respiratory syncytial virus pseudovirus according to any one of claims 1-2.
5. A vaccine, It is characterized in that The vaccine comprises the respiratory syncytial virus pseudovirus according to any one of claims 1-2.
